Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;19(8):1119-25.
doi: 10.1128/CVI.00153-12. Epub 2012 May 30.

Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand

Bao-Zhong Wang  1 , Harvinder S Gill, Sang-Moo Kang, Li Wang, Ying-Chun Wang, Elena V Vassilieva, Richard W Compans
Affiliations

Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand

Bao-Zhong Wang et al. Clin Vaccine Immunol. 2012 Aug.

Abstract

The extracellular domain of matrix protein 2 (M2e) is conserved among influenza A viruses. The goal of this project is to develop enhanced influenza vaccines with broad protective efficacy using the M2e antigen. We designed a membrane-anchored fusion protein by replacing the hyperimmunogenic region of Salmonella enterica serovar Typhimurium flagellin (FliC) with four repeats of M2e (4.M2e-tFliC) and fusing it to a membrane anchor from influenza virus hemagglutinin (HA). The fusion protein was incorporated into influenza virus M1-based virus-like particles (VLPs). These VLPs retained Toll-like receptor 5 (TLR5) agonist activity comparable to that of soluble FliC. Mice immunized with the VLPs by either intramuscular or intranasal immunization showed high levels of systemic M2-specific antibody responses compared to the responses to soluble 4.M2e protein. High mucosal antibody titers were also induced in intranasally immunized mice. All intranasally immunized mice survived lethal challenges with live virus, while intramuscularly immunized mice showed only partial protection, revealing better protection by the intranasal route. These results indicate that a combination of M2e antigens and TLR ligand adjuvants in VLPs has potential for development of a broadly protective influenza A virus vaccine.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Sequences and schematic diagram of constructs. The M2e sequence shown is the consensus of the human influenza A virus M2e sequence. In 4.M2e, four repetitive M2e regions (underlined) are located in a tandem. Sequences in italics are flexible linkers. A 6-histidine tag-encoding DNA was fused in frame. In the membrane-anchored 4.M2e-tFliC, the central immunogenic region of FliC (domain 3 [D3], aa 177 to 401) was replaced by the 4.M2e sequence. The melittin signal peptide (SP) was fused to the N terminus of 4.M2e-tFliC (N-terminal domains 1 and 2 [ND1-2] in FliC) to enable its ectodomain to reach the exocytic pathway and is removed in the mature protein by insect cell signal peptidase (44). The transmembrane and cytoplasmic domains (TM/CT) of A/PR8 virus HA were attached to the C terminus of the 4.M2e-tFliC (C-terminal domains 2 and 1 [CD2-1] in FliC).
Fig 2
Fig 2
Characterization of 4.M2e-tFliC VLPs. (A) Diagram of influenza virus 4.M2e-tFliC VLPs. The membrane-anchored form of the 4.M2e-tFliC is inserted into the lipid bilayer of the envelope. (B) Negative-stain EM of VLP. (C to E) Characterization of VLPs. VLP samples were applied to SDS-polyacrylamide gels, followed by Western blotting. Lanes 1, 4.M2e-tFliC VLPs; lanes 2, M1-only VLPs. Protein bands were detected by mouse anti-FliC antibody (FliC-1) (C), mouse anti-M2e antibody (14C2) (D), and anti-M1 antibody (GA2B; Abcam) (E). (F) TLR5 agonist activity of flagellin. The mouse macrophage cell line RAW264.7, which expresses TLR2 and TLR4 without TLR5, was used to determine the bioactivity of 4.M2e-tFliC VLPs. Soluble recombinant FliC (sFliC) was used as a positive control; M1-only VLPs and recombinant 4.M2e were used as negative controls. TLR5-expressing RAW264.7 cells were prepared by transfection with the vector pUNO-hTLR5 expressing the human TLR5, as described previously (40). Data represent means ± standard deviations (SDs) from triplicate repeats.
Fig 3
Fig 3
Antibody responses. (A) Serum IgG recognizing M2e in immunized mice. To determine serum M2e-specific IgG titers, ELISA plates were coated with 100 μl/well of synthesized M2e peptide (5 μg/ml; at the Emory University Biochemical Core Facility). (B) Endpoint titers of IgG recognizing native M2 protein. MDCK cells were infected with A/PR8 viruses at an MOI of 1. Uninfected cells were used as a control. At 12 h postinfection, cells were washed with PBS and fixed with 0.5% glutaraldehyde. Samples diluted 80-fold were applied to detect antibody binding, as described in Materials and Methods. Data depict the OD450 (mean ± SD) with infected cells, with the background of uninfected cells subtracted. Groups 1 and 2 represent mouse groups immunized with 4.M2e and 4.M2e-tFliC/M1 VLPs, respectively. (C) Lung lavage IgA. IgA endpoint titers were determined as described for the serum IgG endpoint titer in panel A, but the secondary antibody used was HRP-conjugated goat anti-mouse IgA antibody. (D) Lung lavage IgG. Representative data are the geometric mean (GM) ± 95% confidence interval (CI) of six mice in each group at 4 weeks after the last immunization. Asterisks on the top of a bar present the statistical difference of the group to its counterpart in the M2e group. The statistical difference between other groups is labeled with a connecting line. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Fig 4
Fig 4
A/Philippines (H3N2) live virus challenge. Four weeks after the last immunization, 6 mice of each group were infected i.n. with 5 LD50s of mouse-adapted A/Philippines viruses (250 PFU). Survival of mouse groups immunized i.m. (A) or i.n. (B) and body weight changes of i.m. (C) and i.n. (D) groups were monitored and recorded for 15 days to indicate the protective efficacy of the vaccines. In panels C and D, the data represent means of the body weight change (percentage of prechallenge body weight) of 6 mice in each group.
Fig 5
Fig 5
A/PR8 (H1N1) virus challenge. Four weeks after the last immunization, mice were infected i.n. with 5 LD50s of mouse-adapted A/PR8 virus (125 PFU). Survival of mouse groups immunized i.m. (A) or i.n. (B) and body weight changes of groups immunized i.m. (C) or i.n. (D) were monitored and recorded as described in the legend to Fig. 4.
Fig 6
Fig 6
Lung viral load on day 4 postchallenge. Four weeks after the last immunization, three mice in each group were infected i.n. with 5 LD50s of mouse-adapted A/PR8 (H1N1) or A/Philippines (Phi; H3N2) virus. Mouse lungs were collected on day 4 postchallenge. Each lung was ground and cleared in 1 ml of Dulbecco modified Eagle medium. Virus titers of lung extracts were titrated using a standard plaque assay with MDCK cells. Lung viral titer was expressed as the number of PFU/lung. Data depict means ± SDs of three mice from each group. Groups 1 and 2 represent mouse groups immunized i.m. or i.n. with 4.M2e and 4.M2e-tFliC/M1 VLPs, respectively. Statistically significant differences between immunized groups and the naive group are indicated: *, P < 0.05; **, P < 0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acharya R, et al. 2010. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 107:15075–15080 - PMC - PubMed
    1. Andersen-Nissen E, et al. 2005. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc. Natl. Acad. Sci. U. S. A. 102:9247–9252 - PMC - PubMed
    1. Ben-Yedidia T, Arnon R. 1998. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64:9–15 - PubMed
    1. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. 1993. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74(Pt 1):143–146 - PubMed
    1. Brandtzaeg P. 2003. Role of mucosal immunity in influenza. Dev. Biol. (Basel) 115:39–48 - PubMed

Publication types

MeSH terms